A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Boehringer Ingelheim
Teclison Ltd.
Jiangsu HengRui Medicine Co., Ltd.
Exelixis
Novartis
Orano Med LLC
Amgen
RayzeBio, Inc.
ITM Solucin GmbH
Turning Point Therapeutics, Inc.
RayzeBio, Inc.
Boston Scientific Corporation
Legend Biotech USA Inc
Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc.
Hoffmann-La Roche
Eisai Inc.
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Advanced Accelerator Applications
Chimeric Therapeutics
SAPU NANO (US) LLC
Guerbet
Advanced Accelerator Applications
TaiRx, Inc.
ITM Solucin GmbH
Tanabe Pharma America, Inc.
Perspective Therapeutics
Debiopharm International SA
Camurus AB
BioXcel Therapeutics Inc
Novelty Nobility, Inc.
Merck Sharp & Dohme LLC
Sichuan Baili Pharmaceutical Co., Ltd.
Hutchmed
Circle Pharma
ITM Solucin GmbH
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Sinotau Pharmaceutical Group
Ariceum Therapeutics GmbH
Hutchmed
PharmaMar
Nuvation Bio Inc.
Orano Med LLC
Jiangsu HengRui Medicine Co., Ltd.
Hoffmann-La Roche
Hutchmed
Harbour BioMed (Guangzhou) Co. Ltd.
Ascentage Pharma Group Inc.
EpicentRx, Inc.